The objective of the current proposal is to develop a new sensitive technology using the ImmunoSEQ assay platform to prospectively assess the donor-reactive T cell repertoire in non-invasive blood (and/or urine in kidney transplant) samples. It is our hypothesis that comprehensive profiling of donor-reactive T-cell repertoire can be made by using recipient pre-transplant mixed lymphocyte reaction (MLR) versus the donor and the immunoSEQ platform, and that detection of the same donor-reactive clones in post-transplant blood (urine pellets), and/or biopsies is diagnostic of acute rejection. We further posit that longitudinal tracking of pre-identified donor-reactive T cell clones is predictive of post-transplant rejection, or predict progression from subclinical to acute rejection, and that this can be monitored non-invasively in the post-transplant blood (and/or urine pellets) rather than in biopsies.
|Effective start/end date||9/30/17 → 9/29/20|
- U.S. Army Medical Research and Materiel Command (W81XWH-17-1-0679)